133 related articles for article (PubMed ID: 16843536)
1. Cells lytically infected with Epstein-Barr virus are detected and separable by immunoglobulins from EBV-seropositive individuals.
Bhaduri-McIntosh S; Miller G
J Virol Methods; 2006 Oct; 137(1):103-14. PubMed ID: 16843536
[TBL] [Abstract][Full Text] [Related]
2. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
Niller HH; Wolf H; Minarovits J
Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
[TBL] [Abstract][Full Text] [Related]
3. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies.
Westphal EM; Blackstock W; Feng W; Israel B; Kenney SC
Cancer Res; 2000 Oct; 60(20):5781-8. PubMed ID: 11059774
[TBL] [Abstract][Full Text] [Related]
4. Cell cycle arrest and lytic induction of EBV-transformed B lymphoblastoid cells by a histone deacetylase inhibitor, Trichostatin A.
Seo JS; Cho NY; Kim HR; Tsurumi T; Jang YS; Lee WK; Lee SK
Oncol Rep; 2008 Jan; 19(1):93-8. PubMed ID: 18097580
[TBL] [Abstract][Full Text] [Related]
5. Lytic cycle switches of oncogenic human gammaherpesviruses.
Miller G; El-Guindy A; Countryman J; Ye J; Gradoville L
Adv Cancer Res; 2007; 97():81-109. PubMed ID: 17419942
[TBL] [Abstract][Full Text] [Related]
6. A molecular link between malaria and Epstein-Barr virus reactivation.
ChĂȘne A; Donati D; Guerreiro-Cacais AO; Levitsky V; Chen Q; Falk KI; Orem J; Kironde F; Wahlgren M; Bejarano MT
PLoS Pathog; 2007 Jun; 3(6):e80. PubMed ID: 17559303
[TBL] [Abstract][Full Text] [Related]
7. Immune activation suppresses initiation of lytic Epstein-Barr virus infection.
Ladell K; Dorner M; Zauner L; Berger C; Zucol F; Bernasconi M; Niggli FK; Speck RF; Nadal D
Cell Microbiol; 2007 Aug; 9(8):2055-69. PubMed ID: 17419714
[TBL] [Abstract][Full Text] [Related]
8. Serum IgA antibodies to Epstein-Barr virus (EBV) early lytic antigens are present in primary EBV infection.
Bhaduri-McIntosh S; Landry ML; Nikiforow S; Rotenberg M; El-Guindy A; Miller G
J Infect Dis; 2007 Feb; 195(4):483-92. PubMed ID: 17230407
[TBL] [Abstract][Full Text] [Related]
9. Latent and lytic Epstein-Barr virus replication strategies.
Tsurumi T; Fujita M; Kudoh A
Rev Med Virol; 2005; 15(1):3-15. PubMed ID: 15386591
[TBL] [Abstract][Full Text] [Related]
10. Protein kinase C-independent activation of the Epstein-Barr virus lytic cycle.
Gradoville L; Kwa D; El-Guindy A; Miller G
J Virol; 2002 Jun; 76(11):5612-26. PubMed ID: 11991990
[TBL] [Abstract][Full Text] [Related]
11. A concatenated form of Epstein-Barr viral DNA in lymphoblastoid cell lines induced by transfection with BZLF1.
Cho MS; Tran VM
Virology; 1993 Jun; 194(2):838-42. PubMed ID: 8389085
[TBL] [Abstract][Full Text] [Related]
12. EBV lytic-phase protein BGLF5 contributes to TLR9 downregulation during productive infection.
van Gent M; Griffin BD; Berkhoff EG; van Leeuwen D; Boer IG; Buisson M; Hartgers FC; Burmeister WP; Wiertz EJ; Ressing ME
J Immunol; 2011 Feb; 186(3):1694-702. PubMed ID: 21191071
[TBL] [Abstract][Full Text] [Related]
13. Histone hyperacetylation occurs on promoters of lytic cycle regulatory genes in Epstein-Barr virus-infected cell lines which are refractory to disruption of latency by histone deacetylase inhibitors.
Countryman JK; Gradoville L; Miller G
J Virol; 2008 May; 82(10):4706-19. PubMed ID: 18337569
[TBL] [Abstract][Full Text] [Related]
14. Aberrant Epstein-Barr virus persistence in HIV carriers is characterized by anti-Epstein-Barr virus IgA and high cellular viral loads with restricted transcription.
Stevens SJ; Smits PH; Verkuijlen SA; Rockx DA; van Gorp EC; Mulder JW; Middeldorp JM
AIDS; 2007 Oct; 21(16):2141-9. PubMed ID: 18090040
[TBL] [Abstract][Full Text] [Related]
15. Detection of Epstein-Barr virus infection and gene expression in human tumors by microarray analysis.
Li C; Chen RS; Hung SK; Lee YT; Yen CY; Lai YW; Teng RH; Huang JY; Tang YC; Tung CP; Wei TT; Shieh B; Liu ST
J Virol Methods; 2006 May; 133(2):158-66. PubMed ID: 16384612
[TBL] [Abstract][Full Text] [Related]
16. Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins.
Adhikary D; Behrends U; Moosmann A; Witter K; Bornkamm GW; Mautner J
J Exp Med; 2006 Apr; 203(4):995-1006. PubMed ID: 16549597
[TBL] [Abstract][Full Text] [Related]
17. Identification of Novel Small Organic Compounds with Diverse Structures for the Induction of Epstein-Barr Virus (EBV) Lytic Cycle in EBV-Positive Epithelial Malignancies.
Choi CK; Ho DN; Hui KF; Kao RY; Chiang AK
PLoS One; 2015; 10(12):e0145994. PubMed ID: 26717578
[TBL] [Abstract][Full Text] [Related]
18. Cellular STAT3 functions via PCBP2 to restrain Epstein-Barr Virus lytic activation in B lymphocytes.
Koganti S; Clark C; Zhi J; Li X; Chen EI; Chakrabortty S; Hill ER; Bhaduri-McIntosh S
J Virol; 2015 May; 89(9):5002-11. PubMed ID: 25717101
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of STAT3 marks Burkitt lymphoma cells refractory to Epstein-Barr virus lytic cycle induction by HDAC inhibitors.
Daigle D; Megyola C; El-Guindy A; Gradoville L; Tuck D; Miller G; Bhaduri-McIntosh S
J Virol; 2010 Jan; 84(2):993-1004. PubMed ID: 19889776
[TBL] [Abstract][Full Text] [Related]
20. B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders.
Dolcetti R
Autoimmun Rev; 2007 Dec; 7(2):96-101. PubMed ID: 18035317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]